#United States #New York #Class Action #The Gross Law Firm #BioAge Labs

Class Action Lawsuit Filed Against BioAge Labs, Inc. (BIOA)

In a significant development for shareholders of BioAge Labs, Inc. (NASDAQ: BIOA), a class action lawsuit has been initiated by The Gross Law Firm. This complaint is directed towards investors who acquired shares of BioAge Labs during the specified class period, particularly those who purchased stock due to the company’s IPO held on or about September 26, 2024.

Allegations and Stock Decline

The context behind the lawsuit is rooted in a startling announcement made by BioAge Labs on December 6, 2024. The company declared the discontinuation of its STRIDES Phase 2 trial for azelaprag, its leading product candidate. This decision stemmed from concerns surrounding elevated liver transaminase levels among trial participants. At the time of its IPO, BioAge had confidently touted the product's potential benefits for patients undergoing obesity treatment with incretin drugs.

However, this sudden revelation resulted in a drastic decrease in the company’s stock price, plummeting from $20.09 per share the day the news broke to only $4.65 per share the following day. This stark contrast has raised alarm amongst shareholders, fostering the need for legal action to protect their investments.

What This Means for Shareholders

Shareholders who believe they have been adversely affected by these developments are actively encouraged to register with The Gross Law Firm. Potential class members can seek to be appointed as lead plaintiffs; however, those choosing not to take on this role can still partake in any ensuing recovery without any obligations.

The key date to keep in mind is March 10, 2025, which serves as the deadline for registering as a part of this class action. Those wishing to participate should ensure they do not delay, as registering on time is crucial to be included in the case.

Once registered, shareholders will benefit from portfolio monitoring software, which will provide consistent updates regarding the progress and status of the lawsuit. This proactive approach aims to keep investors informed throughout the lifecycle of the case, thereby ensuring transparency and communication.

About The Gross Law Firm

Founded with the mission to safeguard the rights of investors, The Gross Law Firm stands nationally recognized in legal circles, particularly for their class action initiatives. Their focus lies on defending against fraudulent practices and corporate misconduct that lead to financial losses among investors. They emphasize a commitment to corporate accountability and ethical business operations.

Asserting rights to recover losses incurred from misleading statements or omissions made by a company is central to their philosophy. Interested shareholders are invited to learn more and register for this case by exploring their official website, or by directly reaching out to the firm via the contact information provided.

For more information, shareholders can contact The Gross Law Firm at:

• - Phone: (646) 453-8903
• - Email: [email protected]
• - Office Address: 15 West 38th Street, 12th floor, New York, NY, 10018.

In conclusion, current and former shareholders of BioAge Labs, Inc. stand to benefit from getting involved with this class action, as it represents a collective effort to address the significant stock value decline due to the company’s recent decisions. Remember to register before the deadline on March 10, 2025, to ensure your participation in this crucial legal endeavor.